ImmunityBio (IBRX) Non Operating Interest Expenses (2016 - 2026)

For the trailing twelve months through Jun 30, 2026, Non Operating Interest Expenses at ImmunityBio was $58.74 million, down 31.8% year-over-year; for FY2025, it came in at $60.89 million, down 46.9% from FY2024.

• Annual Non Operating Interest Expenses shows a five-year compound annual growth rate of 46.3% (FY2020 to FY2025).
• In prior years, ImmunityBio's Non Operating Interest Expenses was $114.59 million in FY2024 (-11.1%), $128.85 million in FY2023 (+102.9%), $63.52 million in FY2022 (+327.7%) and $14.85 million in FY2021 (+63.6%).
• The Q2 2026 figure stands as the lowest quarterly Non Operating Interest Expenses since Q2 2022.
• On a year-over-year basis, Non Operating Interest Expenses has declined in each of the last ten quarters, with an average decline of 29.4% over the last eight quarters.
• The strongest year-over-year quarter for Non Operating Interest Expenses in the past five years was Q4 2022, with growth of 536.1%; the weakest was Q2 2025, with a decline of 48.1%.
• According to Business Quant data, Non Operating Interest Expenses for the three prior quarters was $14.59 million (Q1 2026), $14.84 million (Q4 2025) and $15.26 million (Q3 2025).